Five FDA peptide-seller letters sharpen the claims-monitoring problem.

On September 1, FDA posted five warning letters issued August 24 to Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations doing business as Tex Peptides. Each letter is case-specific, but all five describe products sold online as unapproved new drugs and misbranded drugs.

The letters extend the claims-monitoring problem beyond the compounded-drug promotion signals FDA emphasized earlier in 2026. The cited evidence includes commercial product pages, summaries of purported research, statements about disease or body-function effects, injectable products, and—in multiple records—bacteriostatic water or reconstitution language.

Research language can still become intended-use evidence. FDA cited descriptions of claimed therapeutic, performance, or body-function effects on commercial pages. The practical review question is not simply whether a page links to research; it is what the page communicates about how the product is expected to be used.

“Research use only” did not end the analysis. In the Peptide Partners letter, FDA expressly addressed the disclaimer and pointed to other website evidence—including bacteriostatic water sold as a solvent for reconstitution—as evidence of intended human injection. The operator task is to review the whole journey, not one footer line.

Injectable risk received explicit attention. FDA repeatedly said injectable products pose serious risks because they bypass important bodily defenses. That does not establish the outcome of any individual product case, but it raises the importance of substance identity, sterility, labeling, reconstitution, and route-specific review.

The product taxonomy overlaps. Across the letters, FDA named products including semaglutide, tirzepatide, retatrutide, SS-31 or elamipretide, tesamorelin, and PT-141 or bremelanotide. A monitoring system should connect each substance to every page and claim surface rather than treating each warning letter as an isolated event.

The legal distinction between an unapproved product sold by a research supplier and patient-specific compounding by a licensed pharmacy did not disappear. Compounded drugs are not FDA approved, but the five new seller letters do not decide whether every compounded preparation is unlawful or whether a drug is appropriate for an individual patient.

The letters also do not establish that a recipient’s present-day pages still contain the cited language, resolve state-law questions, or replace pharmacy, advertising, privacy, professional-practice, and counsel review.

A credible competing interpretation is that an established compliance team already monitors these records reliably. In that case, a separate intelligence service has no value unless it reduces missed changes, review time, or cross-functional handoff friction enough to justify its cost.